Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Kiora Pharmaceuticals (NASDAQ:KPRX) will take part in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.
Rhea-AI Summary
Kiora Pharmaceuticals (NASDAQ:KPRX) will take part in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.
The live presentation is scheduled for Thursday, July 9, 2026 at 2:30 p.m. EDT and will be webcast with a replay available for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – KPRX
In the Jul 2 session, KPRX declined 1.13%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Symposium date
- July 9, 2026
- Piper Sandler Virtual Ophthalmology Symposium presentation date
- Presentation time
- 2:30 p.m. EDT
- Scheduled start time for investor fireside chat
- Replay availability
- 90 days
- Length of time webcast replay will be accessible
Historical Context
-
Preclinical data showed KIO-300 suppressed seizure activity in epilepsy model.
-
Q1 2026 financial results and pipeline update, including ABACUS-2 enrollment status.
-
Publication of Phase 1 ABACUS-1 KIO-301 data and Phase 2 trial initiation.
-
Private placement for up to $24M with upfront proceeds and warrant tranches.
-
Chief Development Officer departure and continued enrollment in KIO-301/KIO-104.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium.
Presentation Details
Date: Thursday, July 9, 2026
Time: 2:30 p.m. Eastern Daylight Time
Live Presentation: Available on Kiora's Investor Relations homepage at ir.kiorapharma.com
Replay: Available for 90 days on Kiora's Investor Relations Events page at ir.kiorapharma.com/news-events/events
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for the treatment of retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of macular edema due to retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Contact:
investors@kiorapharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303675
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.